Is Now the Right Time to Buy Compass Pathways?
Do you ever get the feeling the stock market isn't reading the same news that you are? Compass Pathways (NASDAQ: CMPS) shareholders know that feeling. The clinical-stage drugmaker recently told investors its psilocybin-based treatment hit high marks in a closely watched depression study. Yet instead of the stock rising as you might expect, it fell hard.
Was this just a case of investors selling the news, or is there something else rubbing Wall Street the wrong way about Compass Pathways? And is this latest dip a warning, or an opportunity to buy a top psychedelic stock at a discount?
Image source: Getty Images.
Source Fool.com
